-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Syndax Pharmaceuticals, Lowers Price Target to $43

Benzinga·03/31/2026 13:30:02
Listen to the news
Mizuho analyst Salim Syed maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Outperform and lowers the price target from $45 to $43.